Korro Bio, Inc. (KRRO) Presents at forty fourth Annual J.P. Morgan Healthcare Convention Transcript

Henry Jiang

Everybody. Good morning. Thanks all for becoming a member of us at the moment. My identify is Henry Jiang. I am with the banking group right here at JPMorgan, and it is my pleasure to be introducing Korro Bio at the moment. Becoming a member of us on stage and presenting will likely be Ram Aiyar, President and CEO of Korro Bio. Only a fast notice, we’ll have a while after the presentation for questions, so please wait till then. However with out additional ado, I will move it over to you, Ram.

Ram Aiyar
CEO, President, Interim CFO, Principal Monetary Officer & Director

Additionally, thanks for the JPMorgan Healthcare group for giving us the chance to current right here at the moment. It is nice to see this superb crowd right here. So thanks for being right here. Actually admire it. Hopefully, we’ll inform you a little bit bit about what we do at Korro.

Listed below are my customary forward-looking statements, you possibly can at all times go to the SEC to search out our most newest filings. So what will we do at Korro? At Korro, our imaginative and prescient is to develop transformative medicines for each uncommon in addition to extremely prevalent indications. And so we do this primarily by activating organic pathways. It is a very laborious factor to do. Most modalities are targeted on flattening proteins or flattening sure areas. Gene remedy is the one one the place you possibly can add one other protein or activate alerts. On this case, we use a easy chemically modified oligonucleotide or RNA to go and impact the change, okay? So we do this to make a single base change from an adenosine to inosine by enhancing RNA, not touching DNA in any respect to essentially affect the protein construction